scispace - formally typeset
D

Dt Sleijfer

Researcher at University of Groningen

Publications -  105
Citations -  4205

Dt Sleijfer is an academic researcher from University of Groningen. The author has contributed to research in topics: Testicular cancer & Chemotherapy. The author has an hindex of 34, co-authored 105 publications receiving 4086 citations.

Papers
More filters
Journal ArticleDOI

Cardiovascular morbidity in long-term survivors of metastatic testicular cancer.

TL;DR: In long-term survivors of metastatic testicular cancer, a significantly increased risk for occurrence of cardiac events accompanied by a persisting unfavorable cardiovascular risk profile is observed.
Journal ArticleDOI

Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.

TL;DR: BEP is the most effective combination regimen in the treatment of disseminated nonseminomatous germ cell cancer, and bleomycin cannot be deleted without compromising treatment efficacy, even in good-prognosis patients.
Journal ArticleDOI

Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.

TL;DR: A statistical model that predicts the histology after chemotherapy for metastatic nonseminomatous germ cell tumor (NSGCT) based on well-known and readily available predictors is developed, estimating with high accuracy the Histology at resection, especially necrosis.
Journal Article

Ploidy of primary germ cell tumors of the testis. Pathogenetic and clinical relevance.

TL;DR: The consistent aneuploidy of testicular GCTs of adults might be helpful in the differential diagnosis of primary nongerm cell tumors of the testis, and in differentiating between metastases of testSexual orientation-related tumors and primary extragonadal malignant G CTs.
Journal ArticleDOI

Phase-II study of subcutaneous interleukin-2 in unselected patients with advanced renal-cell cancer on an outpatient basis

TL;DR: Subcutaneous IL-2 is clinically active, has an acceptable toxicity, and can be given to patients with concomitant disease, according to a single-institution phase II study.